ABT - Abbott Laboratories
| Previous Close | 76.60 |
| Open | 76.29 |
| Bid | 75.97 x 800 |
| Ask | 76.38 x 1000 |
| Day's Range | 75.96 - 77.21 |
| 52 Week Range | 60.32 - 80.74 |
| Volume | 5,022,259 |
| Avg. Volume | 5,525,509 |
| Market Cap | 134.025B |
| Beta (3Y Monthly) | 0.83 |
| PE Ratio (TTM) | 51.54 |
| EPS (TTM) | 1.47 |
| Earnings Date | Jul 16, 2019 - Jul 22, 2019 |
| Forward Dividend & Yield | 1.28 (1.61%) |
| Ex-Dividend Date | 2019-04-12 |
| 1y Target Est | 83.06 |
- Simply Wall St.•22 hours ago
Should Abbott Laboratories (NYSE:ABT) Be Part Of Your Dividend Portfolio?
Is Abbott Laboratories (NYSE:ABT) a good dividend stock? How would you know? Dividend paying companies with growing...
- Investopedia•2 days ago
Most Important Mergers and Acquisitions of 2016
While 2016 did not see a $100 billion deal, there were plenty of important multibillion-dollar deals.
- Zacks•2 days ago
Why Is Abbott (ABT) Up 3.6% Since Last Earnings Report?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•3 days ago
New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results
ABBOTT PARK, Ill., May 16, 2019 /PRNewswire/ -- You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying to lose weight.1 The ketogenic or "keto" diet – a high fat, moderate protein and very low carbohydrate eating pattern – is proven to be an effective weight management plan when followed correctly,2 yet not all keto products on the market have the right ratio of macronutrients ("macros") to yield the best results. To address this need, Abbott (ABT) is launching new ZonePerfect® Keto made with 75% fat, 20% protein and 5% carbs.
- PR Newswire•4 days ago
Nearly 9 out of 10 College Students with Student Debt Say It's Important to Find a Company That Offers Loan Relief
ABBOTT PARK, Ill., May 15, 2019 /PRNewswire/ -- Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this spring. Nearly 70% of graduates today have taken out a loan – and a recent survey of college students shows that 9 out of 10 of them are on the hunt for a company with a student loan perk.
- MarketWatch•5 days ago
Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman
As uncertainty over the outcome of Sino-American trade talks grows, so does the possibility of a longer-than-expected negotiations or an all-out trade war, strategists at Goldman Sachs are providing some timely trading strategies.
- PR Newswire•5 days ago
Abbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders
ABBOTT PARK, Ill., May 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research. As part of the agreement, Abbott will provide the company's neuromodulation technologies—including directional deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy—for research related to these NIH initiatives to explore their application for chronic pain and progressive movement disorders, like Parkinson's disease.
- Zacks•6 days ago
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
- Zacks•9 days ago
Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?
Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•10 days ago
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
- Zacks•11 days ago
Top Stock Reports for Verizon, Abbott & Illinois Tool Works
Top Stock Reports for Verizon, Abbott & Illinois Tool Works
- Zacks•11 days ago
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
- Zacks•11 days ago
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
- Reuters•11 days ago
Nestle, rivals vie for big baby formula prize in China's smaller cities
LONDON/BEIJING, May 7 (Reuters) - Nestle plans to launch a new line of baby formula in China this year under an existing brand, targeted at smaller cities, as the world's largest packaged food company tries to lengthen its lead in the world's biggest baby milk market. The new line, discussed exclusively with Reuters, will focus on smaller provincial cities, often in China's western provinces, where greater shipping distances and lower incomes can make some imported brand goods unaffordable, though wealth there is growing. Producers of many consumer staples such as soft drinks and soap had to seek growth in the less-profitable provincial cities years ago, as China's richer eastern markets matured.
- Zacks•12 days ago
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
- Investing.com•12 days ago
Abbott Labs Falls 3%
Investing.com - Abbott Labs (NYSE:ABT) fell by 3.10% to trade at $76.66 by 13:04 (17:04 GMT) on Tuesday on the NYSE exchange.
- PR Newswire•12 days ago
Abbott to Present at UBS Global Healthcare Conference
ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Brian Yoor , executive vice president of finance and chief ...
- Zacks•12 days ago
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
- Zacks•12 days ago
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
- Zacks•12 days ago
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $643 million over the last one-month into ETFs that hold ABT are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. ABT credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•12 days ago
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
- Zacks•13 days ago
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
- CNBC Videos•6 days ago
Is Pinterest a compelling buy? Is Abbott heading to new highs? The desk answers viewer questions
The "Halftime Report" traders answer viewer questions on Abbott Labs, Pinterest, Chevron, and Intel.
